

including plants in Orangeburg and Sumter, South Carolina, and a research and development center in Ann Arbor, Michigan, as well as technology outside the United States which supports that business. Metal Leve and Mahle will cease to have any rights to what was formerly the Metal Leve articulated piston technology once the divestiture required by the proposed Order has been accomplished.

The proposed Order requires that the divestiture be completed within ten days of the Order becoming final. Thus, the Proposed Respondents must file an acceptable application for divestiture well before the proposed Order is made final, so that the application can be placed on the public record for thirty days, the Commission can determine whether to approve it, and Respondents can complete the required divestiture within the time period set forth in the proposed Order.

If the required divestiture is not accomplished within ten days of the Order being made final, then a trustee may be appointed to divest the business. The trustee may add some or all of the Metal Leve, S.A. piston business to accomplish the divestiture. This crown jewel provision ensures that the required divestiture will be accomplished in a timely manner.

A Hold Separate Agreement accepted by the Commission on August 30, 1996, will continue in effect until the divestiture required by the proposed Order is accomplished. The Hold Separate requires Metal Leve to be operated independently of Mahle on a worldwide basis and requires Metal Leve, Inc. to be maintained as a viable competitor in the business in which it was engaged prior to Mahle's acquisition of Metal Leve.

Finally, the proposed Order prohibits Mahle or Metal Leve from acquiring any interest in any other company engaged in the manufacture or sale of articulated pistons in the United States, without prior notice to the Commission, for a period of ten (10) years.

The purpose of this analysis is to facilitate public comment on the proposed Order. This analysis is not intended to constitute an official interpretation of the Agreement or the proposed Order or in any way to modify the terms of the Agreement or the proposed Order.

Donald S. Clark,
Secretary.

[FR Doc. 97-5708 Filed 3-6-97; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of Meeting of the National Bioethics Advisory Commission (NBAC), Genetics Subcommittee

Correction notice for previously published notice (Published on February 26, 1997, Page 8743, 2nd Column). The date is corrected to read: Date: Wednesday, March 5, 1997, 7:00 a.m. to 1:00 p.m.

FOR FURTHER INFORMATION CONTACT: Ms. Henrietta Hyatt-Knorr, National Bioethics Advisory Commission, MSC-7508, 6100 Executive Boulevard, Suite 3C01, Rockville, Maryland 20892-7508, telephone 301-402-4242, fax number 301-480-6900.

Dated: February 26, 1997.
Henrietta Hyatt-Knorr,
Acting Deputy Director, National Bioethics Advisory Commission.
[FR Doc. 97-5690 Filed 3-4-97; 2:25 pm]
BILLING CODE 4160-17-M

Meeting of the National Bioethics Advisory Commission (NBAC)

SUMMARY: Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is given of a meeting of the National Bioethics Advisory Commission. The Commission members will address the bioethical issues arising from the research on human biology and behavior, and in the applications of that research including clinical. They will also begin a review of the legal and ethical issues associated with the recent report of a technique of cloning sheep. The public is invited to speak on any of these issues and opportunities for statements will be provided.

DATES: Thursday, March 13, 1997, 8 a.m. to 4:30 p.m., and Friday, March 14, 1997, 8 a.m. to 4:30 p.m.

LOCATION: The Commission will meet at the Watergate Hotel, Continental Chesapeake Extender Room, 2650 Virginia Avenue, NW, Washington, DC.

SUPPLEMENTARY INFORMATION: The President established the National Bioethics Advisory Commission (NBAC) by Executive Order 12975 on October 3, 1995. The charter of the Commission was signed on July 26, 1996. The first meeting took place on October 4, 1996. The mission of the NBAC is to advise and make recommendations to the National Science and Technology Council and other entities on bioethical issues arising from the research on human biology and behavior, and in the applications of that research. On

February 24, 1997, the President instructed the Commission to undertake a review of the legal and ethical issues associated with the recent report of a technique for cloning sheep. This scientific discovery raises a host of important issues including serious ethical questions, in particular the possible use of this technique to clone human embryos, as well as the promise of benefits in a number of areas.

Tentative Agenda

The Commission will 1) receive reports from its subcommittees, 2) discuss and plan the Commission's 90-day report to the President on issues of cloning, and 3) listen to presentations from the public.

Public Participation

The meeting is open to the public with attendance limited by the availability of space. Members of the public who wish to present oral statements should contact the Acting Deputy Executive Director of the NBAC by telephone, fax machine, or mail as shown below as soon as possible, prior to the meeting. The Chair of the NBAC will reserve time for presentations by persons requesting an opportunity to speak. The order of speakers will be assigned either on a first come, first serve basis or along other considerations. Individuals unable to make oral presentations are encouraged to mail or fax their comments to the NBAC at least two business days prior to the meeting for distribution to the subcommittee members and inclusion in the record. We urge anyone planning to speak to call the NBAC office two or three days before the meeting to obtain information on the final logistical arrangements.

Persons needing special assistance, such as sign language interpretation or other special accommodations, should contact NBAC staff at the address or telephone number listed below as soon as possible.

FOR FURTHER INFORMATION CONTACT: Ms. Henrietta D. Hyatt-Knorr, National Bioethics Advisory Commission, MSC-7508, 6100 Executive Boulevard, Suite 3C01, Rockville, Maryland 20892-7508, telephone 301-402-4242, fax number 301-480-6900.

Dated: February 25, 1997.
Henrietta Hyatt-Knorr,
Acting Deputy Executive Director, National Bioethics Advisory Commission.

[FR Doc. 97-5691 Filed 3-6-97; 8:45 am]

BILLING CODE 4160-17-P